MOBILE VIEW  | 

1,1,1,2,3,3,3-HEPTAFLUOROPROPANE

Classification   |    Detailed evidence-based information

Therapeutic Toxic Class

    A) 1,1,1,2,3,3,3-Heptafluoropropane is a fluorinated hydrocarbon.

Specific Substances

    A) No Synonyms were found in group or single elements
    1.2.1) MOLECULAR FORMULA
    1) C3-F7-H

Available Forms Sources

    A) USES
    1) 1,1,1,2,3,3,3-Heptafluoropropane has been proposed by the Air and Energy Engineering Research Laboratory of the US Environmental Protection Agency as a potential replacement for the chlorofluorocarbon CFC 12 (Clayton & Clayton, 1994).

Life Support

    A) This overview assumes that basic life support measures have been instituted.

Clinical Effects

    0.2.1) SUMMARY OF EXPOSURE
    A) 1,1,1,2,3,3,3-Heptafluoropropane has been proposed as a possible replacement for the chlorofluorocarbon, CFC 12. Few reports of adverse effects were found for 1,1,1,2,3,3,3-heptafluoropropane. The following effects are based on those of fluorinated hydrocarbons in general. Effects attributed specifically to 1,1,1,2,3,3,3-heptafluoropropane are noted.
    B) LOW CONCENTRATION -
    1) Inhalation of fluorinated hydrocarbons, such as those from leaking air conditioners or refrigerators, usually result in transient eye, nose, and throat irritation. Palpitations and lightheadedness may also be seen.
    C) HIGH CONCENTRATION -
    1) Hexafluoropropane can cause asphyxia by displacement of oxygen from the breathing atmosphere.
    a) Simple asphyxiants displace oxygen from the breathing atmosphere primarily in enclosed spaces and result in hypoxemia. Air hunger, fatigue, decreased vision, mood disturbances, numbness of extremities, headache, confusion, decreased coordination and judgment, cyanosis, and unconsciousness may be noted.
    2) Fluorocarbons have been involved in "sudden sniffing deaths" in aerosol propellant abusers.
    a) Fluorocarbons lower the myocardial threshold to the arrhythmogenic action of injected epinephrine in experimental animals.
    3) Exposure to thermal decomposition products can cause irritation of the eyes, nose, throat, and respiratory tract, and could lead to chemical pneumonitis or noncardiogenic pulmonary edema.
    0.2.4) HEENT
    A) Eye irritation may occur. Ocular instillation of some fluorocarbons results in corneal burns in rabbits.
    B) Nasal irritation may occur.
    C) Frostbite of the lips, tongue, buccal mucosa and hard palate developed in one case after deliberate inhalation of a chlorofluorocarbon.
    0.2.5) CARDIOVASCULAR
    A) Inhalation of high concentrations of some fluorocarbons is associated with the development of refractory ventricular dysrhythmias and sudden death, believed to be secondary to a lowering of the myocardial threshold to the arrhythmogenic action of endogenous catecholamines. Some individuals may be susceptible to arrhythmogenic effects at lower concentrations.
    0.2.6) RESPIRATORY
    A) Pulmonary irritation, bronchial constriction, cough, dyspnea, and chest tightness may develop after inhalation. Pulmonary edema is an autopsy finding in fatal cases of fluorocarbon exposure.
    0.2.7) NEUROLOGIC
    A) Headache, dizziness, and disorientation are common with exposure to fluorocarbons. Cerebral edema may be found at autopsy.
    0.2.8) GASTROINTESTINAL
    A) Nausea may develop. Ingestion of a small amount of trichlorofluoromethane resulted in necrosis and perforation of the stomach in one patient.
    0.2.9) HEPATIC
    A) Jaundice and mild elevations in transaminases rarely develop after inhalational exposure or ingestion of fluorocarbons.
    0.2.14) DERMATOLOGIC
    A) Dermal contact with fluorocarbons may result in defatting, irritation, or contact dermatitis. Severe frostbite was reported as a rare effect of dermal freon exposure. Injection may cause transient pain, erythema and edema.
    0.2.15) MUSCULOSKELETAL
    A) Rhabdomyolysis has been reported after exposure to fluorocarbons in a worker susceptible to malignant hyperthermia, and in freon abusers following intentional inhalation. Compartment syndrome is a rare complication of severe exposure to fluorocarbons.
    0.2.20) REPRODUCTIVE
    A) Heptafluoropropane was not teratogenic in rats by the inhalation route.
    0.2.21) CARCINOGENICITY
    A) At the time of this review, no data were available to assess the carcinogenic potential of this agent.

Laboratory Monitoring

    A) Fluorinated hydrocarbon plasma levels are not clinically useful.
    B) No specific laboratory evaluation (CBC, electrolyte, urinalysis, etc) is needed unless indicated by the patients presentation.
    C) Obtain baseline pulse oximetry or arterial blood gas analysis.
    D) Monitor ECG.

Treatment Overview

    0.4.2) ORAL/PARENTERAL EXPOSURE
    A) Few oral exposures to liquid fluorinated hydrocarbons have been described including a single ingestion resulting in gastric perforation. The manufacturer of one product does not recommend inducing emesis following exposure due to a low potential for toxicity. Following ingestion of a large amount, however, gastric lavage and activated charcoal may be considered in alert patients.
    B) ACTIVATED CHARCOAL: Administer charcoal as a slurry (240 mL water/30 g charcoal). Usual dose: 25 to 100 g in adults/adolescents, 25 to 50 g in children (1 to 12 years), and 1 g/kg in infants less than 1 year old.
    C) Significant esophageal or gastrointestinal tract irritation or burns may occur following ingestion. The possible benefit of early removal of some ingested material by cautious gastric lavage must be weighed against potential complications of bleeding or perforation.
    0.4.3) INHALATION EXPOSURE
    A) INHALATION: Move patient to fresh air. Monitor for respiratory distress. If cough or difficulty breathing develops, evaluate for respiratory tract irritation, bronchitis, or pneumonitis. Administer oxygen and assist ventilation as required. Treat bronchospasm with an inhaled beta2-adrenergic agonist. Consider systemic corticosteroids in patients with significant bronchospasm.
    B) Monitor ECG and vital signs. Cardiopulmonary resuscitation may be necessary.
    C) PROVIDE A QUIET CALM ATMOSPHERE - to prevent adrenalin surge if the patient is seen before the onset of cardiac arrhythmias. Minimize physical exertion.
    D) MONITOR - pulse oximetry or arterial blood gases.
    E) Provide symptomatic and supportive care.
    0.4.4) EYE EXPOSURE
    A) DECONTAMINATION: Remove contact lenses and irrigate exposed eyes with copious amounts of room temperature 0.9% saline or water for at least 15 minutes. If irritation, pain, swelling, lacrimation, or photophobia persist after 15 minutes of irrigation, the patient should be seen in a healthcare facility.
    0.4.5) DERMAL EXPOSURE
    A) OVERVIEW
    1) DECONTAMINATION: Remove contaminated clothing and jewelry and place them in plastic bags. Wash exposed areas with soap and water for 10 to 15 minutes with gentle sponging to avoid skin breakdown. A physician may need to examine the area if irritation or pain persists (Burgess et al, 1999).

Range Of Toxicity

    A) Fluorinated hydrocarbons are very toxic when inhaled in high concentrations and/or for extended periods. At lower concentrations or brief exposure, they may cause transient eye, nose, and throat irritation. There is significant interindividual variation and it is difficult to predict which patient will exhibit symptoms following exposure.
    B) 1,1,1,2,3,3,3-Heptafluoropropane can displace sufficient oxygen from the air to act as a simple asphyxiant at concentrations greater than approximately 100,000 ppm. The effective fire extinguishing concentration is 7% (70,000 ppm).
    1) Signs of asphyxia will be noted when atmospheric oxygen is displaced to less than 15% to 16%, and unconsciousness leading to death will occur when it is less than 6% to 8%.

Summary Of Exposure

    A) 1,1,1,2,3,3,3-Heptafluoropropane has been proposed as a possible replacement for the chlorofluorocarbon, CFC 12. Few reports of adverse effects were found for 1,1,1,2,3,3,3-heptafluoropropane. The following effects are based on those of fluorinated hydrocarbons in general. Effects attributed specifically to 1,1,1,2,3,3,3-heptafluoropropane are noted.
    B) LOW CONCENTRATION -
    1) Inhalation of fluorinated hydrocarbons, such as those from leaking air conditioners or refrigerators, usually result in transient eye, nose, and throat irritation. Palpitations and lightheadedness may also be seen.
    C) HIGH CONCENTRATION -
    1) Hexafluoropropane can cause asphyxia by displacement of oxygen from the breathing atmosphere.
    a) Simple asphyxiants displace oxygen from the breathing atmosphere primarily in enclosed spaces and result in hypoxemia. Air hunger, fatigue, decreased vision, mood disturbances, numbness of extremities, headache, confusion, decreased coordination and judgment, cyanosis, and unconsciousness may be noted.
    2) Fluorocarbons have been involved in "sudden sniffing deaths" in aerosol propellant abusers.
    a) Fluorocarbons lower the myocardial threshold to the arrhythmogenic action of injected epinephrine in experimental animals.
    3) Exposure to thermal decomposition products can cause irritation of the eyes, nose, throat, and respiratory tract, and could lead to chemical pneumonitis or noncardiogenic pulmonary edema.

Heent

    3.4.1) SUMMARY
    A) Eye irritation may occur. Ocular instillation of some fluorocarbons results in corneal burns in rabbits.
    B) Nasal irritation may occur.
    C) Frostbite of the lips, tongue, buccal mucosa and hard palate developed in one case after deliberate inhalation of a chlorofluorocarbon.
    3.4.3) EYES
    A) IRRITATION - Eye irritation and burning may occur with exposure to fluorocarbons (Holness & House, 1992).
    B) CORNEAL EDEMA - Was described in 2 patients after direct application of a chlorofluorocarbon to the eye in a surgical procedure (Miller et al, 1964).
    C) No significant injuries have been reported in the literature from accidental ocular exposure to fluorocarbons from pressurized containers or refrigerator liquids (Grant, 1986), presumably due to rapid reflex closure of the eyes.
    3.4.5) NOSE
    A) Nasal irritation occurs with exposure to fluorocarbons (Holness & House, 1992).
    3.4.6) THROAT
    A) FROSTBITE - of the lips, tongue, buccal mucosa, and hard palate developed in a man after deliberate inhalation of a propellant containing propane and a chlorofluorocarbon (Elliot, 1991).

Cardiovascular

    3.5.1) SUMMARY
    A) Inhalation of high concentrations of some fluorocarbons is associated with the development of refractory ventricular dysrhythmias and sudden death, believed to be secondary to a lowering of the myocardial threshold to the arrhythmogenic action of endogenous catecholamines. Some individuals may be susceptible to arrhythmogenic effects at lower concentrations.
    3.5.2) CLINICAL EFFECTS
    A) CONDUCTION DISORDER OF THE HEART
    1) HIGH CONCENTRATIONS - Ventricular fibrillation and ventricular tachycardia have been reported with inhalation exposures to high concentrations of fluorocarbons, usually deliberate abuse or industrial use or spills in poorly ventilated areas (McGee et al, 1990; Lerman et al, 1991; Steadman et al, 1984; Clark et al, 1985; May & Blotzer, 1984; Brady et al, 1994).
    2) LOW CONCENTRATIONS - No clear connection between exposure and cardiac dysrhythmias was found in 6 refrigerator repairmen who were monitored for 24 hours in one day each, with and without exposure (Antti-Poika et al, 1990).
    a) Peak concentration and average level of fluorocarbon exposure reported in the breathing zone were 3200 cm(3)/m(3) and 170 cm(3)/m(3), respectively.
    b) One subject in the exposed group had an arrhythmic tendency (frequent unifocal ventricular ectopic beats that often occurred as bigeminy or trigeminy) susceptible to different arrhythmogenic agents such as fluorocarbons and alcohol. Medical examination prior to inclusion attempted to rule out preexisting cardiovascular disease.
    3) MECHANISM - Fluorinated hydrocarbons are believed to cause lower the myocardial threshold to the arrhythmogenic action of endogenous catecholamines (Voge, 1989).
    4) Once cardiac dysrhythmias develop, they are difficult to reverse. Ventricular fibrillation that develops following exposure to fluorinated hydrocarbons can be treated by cardioversion, which, however, is not always successful (Lown, 1977; Lerman et al, 1991).
    B) DEAD - SUDDEN DEATH
    1) Patients are often described as inhaling fluorinated hydrocarbons, becoming "high," and then developing agitation, being frightened, or engaging in physical exertion (presumably associated with increased endogenous catecholamine levels), followed by sudden collapse (Smeeton, 1985; Garriott & Petty, 1980; Kamm, 1975).
    3.5.3) ANIMAL EFFECTS
    A) ANIMAL STUDIES
    1) DYSRHYTHMIA
    a) In dogs, inhalation of fluorinated hydrocarbon vapors causes bradycardia followed by junctional or ventricular escape rhythms, with deterioration to asystole or ventricular fibrillation in some animals (Flowers & Horan, 1972a; Flowers & Horan 1972b).
    b) This occurs despite maintenance of normal oxygen and carbon dioxide tensions, pH, base excess, and serum carbon dioxide.
    c) Epinephrine doses that produced minimal ECG alterations when administered alone, produced ventricular tachycardia and fibrillation when administered to dogs pretreated with the fluorocarbon compound, bromochlorodifluoromethane (Beck et al, 1973).

Respiratory

    3.6.1) SUMMARY
    A) Pulmonary irritation, bronchial constriction, cough, dyspnea, and chest tightness may develop after inhalation. Pulmonary edema is an autopsy finding in fatal cases of fluorocarbon exposure.
    3.6.2) CLINICAL EFFECTS
    A) BRONCHOSPASM
    1) Fluorinated hydrocarbons may cause bronchial constriction when inhaled. Inhalation of a fluorinated hydrocarbon aerosol produced a 20% or greater decrease in FEV1 in asthmatic patients (Sterling & Batten, 1976).
    2) OCCUPATIONAL ASTHMA - has been reported in patients working with heated freon, although exposure to combustion products (hydrochloric acid, chlorine, phosgene) may have contributed to this effect (Malo et al, 1984; Field, 1985).
    B) IRRITATION SYMPTOM
    1) Fluorinated hydrocarbons may cause lung irritation, cough, and sore throat if inhaled (Holness & House, 1992).
    C) DYSPNEA
    1) Dyspnea is an early symptom of severe exposure to fluorocarbons and is also reported with exposure to lower concentrations (Lerman et al, 1991; Holness & House, 1992).
    D) ACUTE LUNG INJURY
    1) Pulmonary edema has been an autopsy finding in fatal cases of exposure to other fluorocarbons (McGee et al, 1990; Lerman et al, 1991; Kamm, 1975; Morita et al, 1977).
    E) LARYNGITIS
    1) CROUP - An 11-year-old child developed severe croup requiring intubation and pulmonary edema after inhaling a product containing capsaicin and fluorinated hydrocarbons (Winograd, 1977).
    F) LACK OF EFFECT
    1) ARTERIAL BLOOD GASES - Freon does not normally lower arterial oxygen tension, change pH, nor increase arterial carbon dioxide tension. Whether or not this would also be true of 1,1,1,2,3,3,3-heptafluoropropane is not known.

Neurologic

    3.7.1) SUMMARY
    A) Headache, dizziness, and disorientation are common with exposure to fluorocarbons. Cerebral edema may be found at autopsy.
    3.7.2) CLINICAL EFFECTS
    A) HEADACHE
    1) Headache is a common complaint of persons exposed to fluorocarbons; reported in 71% of 31 workers exposed to bromotrifluoromethane (Holness & House).
    B) DIZZINESS
    1) Dizziness was an early symptom noted by soldiers exposed to bromochlorodifluoromethane in a battle tank (Lerman et al, 1991). Lightheadedness was a common complaint (68%) among 31 workers exposed to bromotrifluoromethane (Holness & House, 1992).
    C) CLOUDED CONSCIOUSNESS
    1) DISORIENTATION - Disorientation was a common complaint (29%) among 31 workers exposed to bromotrifluoromethane (Holness & House, 1992).
    D) CEREBRAL EDEMA
    1) Cerebral edema may be found on autopsy after severe inhalation exposure to fluorocarbons (Lerman et al, 1991; Kamm, 1975).
    E) ALTERED MENTAL STATUS
    1) PSYCHOORGANIC SYNDROME - Neuropsychological testing revealed a syndrome of impaired psychomotor speed, impaired learning and memory, and emotional lability in 7 of 21 workers chronically exposed to the fluorocarbon, 1,1,2-trichloro-1,2,2-trifluoroethane (Rasmussen et al, 1988).
    2) Four of these workers had previously been exposed to 1,1,1-trichloroethane, while three had no other solvent exposure.

Gastrointestinal

    3.8.1) SUMMARY
    A) Nausea may develop. Ingestion of a small amount of trichlorofluoromethane resulted in necrosis and perforation of the stomach in one patient.
    3.8.2) CLINICAL EFFECTS
    A) NAUSEA
    1) Nausea developed in 10% of 31 workers exposed to bromotrifluoromethane (Holness & House, 1992).
    B) PERFORATION OF INTESTINE
    1) MUCOSAL INJURY - Mucosal necrosis and perforation of the stomach developed in one patient who ingested a small amount of trichlorofluoromethane (Haj et al, 1980).

Hepatic

    3.9.1) SUMMARY
    A) Jaundice and mild elevations in transaminases rarely develop after inhalational exposure or ingestion of fluorocarbons.
    3.9.2) CLINICAL EFFECTS
    A) LIVER DAMAGE
    1) HEPATIC INJURY - Jaundice and mild elevations of transaminases have been reported rarely after significant fluorocarbon inhalation exposure or ingestion (Haj et al, 1980; Steadman et al, 1984). Brady et al (1994) reported a case of intentional freon inhalation (5 to 6 deep inhalations) concomitant with ethanol ingestion, which resulted in a small increase in liver transaminases.

Dermatologic

    3.14.1) SUMMARY
    A) Dermal contact with fluorocarbons may result in defatting, irritation, or contact dermatitis. Severe frostbite was reported as a rare effect of dermal freon exposure. Injection may cause transient pain, erythema and edema.
    3.14.2) CLINICAL EFFECTS
    A) DERMATITIS
    1) Fluorocarbons may produce contact dermatitis (Proctor & Hughes, 1978; Valdivieso et al, 1987).
    B) SKIN IRRITATION
    1) Freon solvents are degreasers. Defatting of the skin and erythema may occur after direct contact.
    C) CHEMICAL BURN
    1) Chemical burns were reported in 16 cases during a 7-year period following mishaps related to the fluorocarbon, Freon 113 (Voge, 1989).
    D) INJECTION SITE REACTION
    1) ACCIDENTAL INJECTION -
    a) Four adults who received accidental injections of Freon 113(R) in the hand, knee, elbow, and forehead experienced temporary local redness which progressed over 30 to 40 minutes to more widespread blotchy redness, and then subsided. No other manifestations were noted (Personal Communication, 1988).
    b) Goetting et al (1992) report 4 cases of accidental Freon injection with edema, crepitance, and transient pain. All injuries healed with no lasting sequelae following conservative treatment.
    c) High pressure injection of a mixture of isopropanol and freon into a finger resulted in initial pain from the injection site to the axilla, which resolved over several hours. There was minimal tissue injury (Craig, 1984).
    E) FROSTBITE
    1) Frostbite is a rare complication of direct freon exposure.
    2) CASE REPORT/ADULT - Severe frostbite of the hand and shoulder developed after direct close-range exposure to the fluorocarbon, monochlorodifluoromethane, for an unknown period of time.
    a) The patient presented 14 hours after exposure with compartment syndrome of the volar forearm and the adductor and interosseous compartments of the hand. Necrosis developed despite fasciotomy, requiring amputation of the fourth and fifth digits and ulnar half of the hand (Wegener et al, 1991).

Musculoskeletal

    3.15.1) SUMMARY
    A) Rhabdomyolysis has been reported after exposure to fluorocarbons in a worker susceptible to malignant hyperthermia, and in freon abusers following intentional inhalation. Compartment syndrome is a rare complication of severe exposure to fluorocarbons.
    3.15.2) CLINICAL EFFECTS
    A) RHABDOMYOLYSIS
    1) CASE REPORT/ADULT - A 43-year-old man susceptible to malignant hyperthermia (shown by in vitro muscle testing), developed malaise, stiffness, and weakness in the forearms after taking a job that involved discharging bromochlorodifluoromethane fire extinguishers. Symptoms were associated with CPK levels of 1056 IU/L (Denborough & Hopkkinson, 1988).
    2) Brady et al (1994) report a case of cardiac arrest from intentional Freon inhalation resulting in rhabdomyolysis with an increase in CPK originating entirely from skeletal muscle.
    B) COMPARTMENT SYNDROME
    1) Compartment syndrome is a rare complication of direct freon exposure.
    2) CASE REPORT/ADULT - Severe frostbite of the hand and shoulder developed after direct close-range exposure to monochlorodifluoromethane for an unknown period of time.
    a) The patient presented 14 hours after exposure with compartment syndrome of the volar forearm and the adductor and interosseous compartments of the hand. Necrosis developed despite fasciotomy, requiring amputation of the fourth and fifth digits and ulnar half of the hand (Wegener et al, 1991).

Reproductive

    3.20.1) SUMMARY
    A) Heptafluoropropane was not teratogenic in rats by the inhalation route.
    3.20.2) TERATOGENICITY
    A) LACK OF EFFECT
    1) Heptafluoropropane was not teratogenic in rats exposed to concentrations as high as 105,000 ppm for 6 hours daily; the dams required supplemental oxygen at this high concentration (Nemec et al, 1994).
    3.20.3) EFFECTS IN PREGNANCY
    A) LACK OF INFORMATION
    1) At the time of this review, no data were available to assess the potential effects of exposure to this agent during pregnancy or lactation.
    3.20.4) EFFECTS DURING BREAST-FEEDING
    A) LACK OF INFORMATION
    1) At the time of this review, no data were available to assess the potential effects of exposure to this agent during pregnancy or lactation.

Carcinogenicity

    3.21.1) IARC CATEGORY
    A) IARC Carcinogenicity Ratings for CAS431-89-0 (International Agency for Research on Cancer (IARC), 2016; International Agency for Research on Cancer, 2015; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010a; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2008; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2007; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2006; IARC, 2004):
    1) Not Listed
    3.21.2) SUMMARY/HUMAN
    A) At the time of this review, no data were available to assess the carcinogenic potential of this agent.
    3.21.3) HUMAN STUDIES
    A) LACK OF INFORMATION
    1) At the time of this review, no data were available to assess the carcinogenic potential of this agent.

Genotoxicity

    A) At the time of this review, no data were available to assess the mutagenic or genotoxic potential of this agent.

Monitoring Parameters Levels

    4.1.1) SUMMARY
    A) Fluorinated hydrocarbon plasma levels are not clinically useful.
    B) No specific laboratory evaluation (CBC, electrolyte, urinalysis, etc) is needed unless indicated by the patients presentation.
    C) Obtain baseline pulse oximetry or arterial blood gas analysis.
    D) Monitor ECG.
    4.1.2) SERUM/BLOOD
    A) ACID/BASE
    1) Monitor arterial blood gases in patients with significant exposure.
    B) BLOOD/SERUM CHEMISTRY
    1) Fluorinated hydrocarbon plasma levels are not clinically useful.
    C) OTHER
    1) No specific laboratory evaluation (CBC, electrolytes, urinalysis, etc) is needed unless indicated by the patient's presentation.
    4.1.4) OTHER
    A) OTHER
    1) ECG
    a) Monitor ECG.
    2) OXYGEN SATURATION
    a) PULSE OXIMETRY INDICATIONS - To obtain continuous, noninvasive measurement of arterial saturation in patients with respiratory complaints and those requiring assisted or mechanical ventilation (Galdun et al, 1989; Jones et al, 1988; Rose & Wolfson, 1989).
    b) ACCURACY - Accurate for oxygen saturations between 65% and 100% and correlates well with ABGs (Jones et al, 1988; Yelderman & New, 1983). Factors affecting accuracy include (Galdun et al, 1989; Rose & Wolfson, 1989; Bowes et al, 1989; Phillips et al, 1989):
    1) Decreased cardiac output with poor peripheral perfusion (most significant)
    2) Patient or transducer movement
    3) Increased bilirubin levels
    4) Hypothermia
    5) Electrical or optical interference
    6) Carboxyhemoglobin or methemoglobin
    7) Anemia <5 g/dL Hb
    8) Dark nail polish
    9) Nonpulsating vascular bed
    10) Presence of intravascular dyes
    c) DISADVANTAGES - Relative insensitivity to changes in oxygenation occurring in upper portion of oxyhemoglobin dissociation curve; less sensitive than ABGs for detecting changes in pO2, especially in higher ranges of pO2 values (Rose & Wolfson, 1989).

Methods

    A) CHROMATOGRAPHY
    1) Identification of some fluorocarbons in blood can be obtained by flame ionization gas chromatography (Garriott & Petty, 1980), although such measurements are not useful clinically to assess exposed patients.

Life Support

    A) Support respiratory and cardiovascular function.

Patient Disposition

    6.3.1) DISPOSITION/ORAL EXPOSURE
    6.3.1.5) OBSERVATION CRITERIA/ORAL
    A) Patients symptomatic following exposure should be observed in a controlled setting until all signs and symptoms have fully resolved.

Monitoring

    A) Fluorinated hydrocarbon plasma levels are not clinically useful.
    B) No specific laboratory evaluation (CBC, electrolyte, urinalysis, etc) is needed unless indicated by the patients presentation.
    C) Obtain baseline pulse oximetry or arterial blood gas analysis.
    D) Monitor ECG.

Oral Exposure

    6.5.2) PREVENTION OF ABSORPTION
    A) EMESIS/NOT RECOMMENDED
    1) Few oral exposures to liquid fluorinated hydrocarbons have been described. A single case of gastric perforation following ingestion of trichlorofluoromethane has been reported.
    2) The manufacturer of one product does not recommend inducing emesis following exposure due to a low potential for toxicity. Activated charcoal may be indicated after large ingestions.
    B) ACTIVATED CHARCOAL
    1) CHARCOAL ADMINISTRATION
    a) Consider administration of activated charcoal after a potentially toxic ingestion (Chyka et al, 2005). Administer charcoal as an aqueous slurry; most effective when administered within one hour of ingestion.
    2) CHARCOAL DOSE
    a) Use a minimum of 240 milliliters of water per 30 grams charcoal (FDA, 1985). Optimum dose not established; usual dose is 25 to 100 grams in adults and adolescents; 25 to 50 grams in children aged 1 to 12 years (or 0.5 to 1 gram/kilogram body weight) ; and 0.5 to 1 gram/kilogram in infants up to 1 year old (Chyka et al, 2005).
    1) Routine use of a cathartic with activated charcoal is NOT recommended as there is no evidence that cathartics reduce drug absorption and cathartics are known to cause adverse effects such as nausea, vomiting, abdominal cramps, electrolyte imbalances and occasionally hypotension (None Listed, 2004).
    b) ADVERSE EFFECTS/CONTRAINDICATIONS
    1) Complications: emesis, aspiration (Chyka et al, 2005). Aspiration may be complicated by acute respiratory failure, ARDS, bronchiolitis obliterans or chronic lung disease (Golej et al, 2001; Graff et al, 2002; Pollack et al, 1981; Harris & Filandrinos, 1993; Elliot et al, 1989; Rau et al, 1988; Golej et al, 2001; Graff et al, 2002). Refer to the ACTIVATED CHARCOAL/TREATMENT management for further information.
    2) Contraindications: unprotected airway (increases risk/severity of aspiration) , nonfunctioning gastrointestinal tract, uncontrolled vomiting, and ingestion of most hydrocarbons (Chyka et al, 2005).
    6.5.3) TREATMENT
    A) GENERAL TREATMENT
    1) Treatment should include recommendations listed in the INHALATION EXPOSURE section when appropriate.

Inhalation Exposure

    6.7.1) DECONTAMINATION
    A) Move patient from the toxic environment to fresh air. Monitor for respiratory distress. If cough or difficulty in breathing develops, evaluate for hypoxia, respiratory tract irritation, bronchitis, or pneumonitis.
    B) OBSERVATION: Carefully observe patients with inhalation exposure for the development of any systemic signs or symptoms and administer symptomatic treatment as necessary.
    C) INITIAL TREATMENT: Administer 100% humidified supplemental oxygen, perform endotracheal intubation and provide assisted ventilation as required. Administer inhaled beta-2 adrenergic agonists, if bronchospasm develops. Consider systemic corticosteroids in patients with significant bronchospasm (National Heart,Lung,and Blood Institute, 2007). Exposed skin and eyes should be flushed with copious amounts of water.
    6.7.2) TREATMENT
    A) SUPPORT
    1) Cardio-pulmonary resuscitation may be necessary.
    2) Patient's cardiac function should be monitored.
    3) Patient should be monitored closely and treated symptomatically.
    4) QUIET ATMOSPHERE - Provide a calm quiet atmosphere to prevent adrenalin surge if patient is seen before cardiac arrhythmias occur. Minimize physical exertion.
    B) MONITORING OF PATIENT
    1) BLOOD GASES - Monitor arterial blood gases in patients with respiratory symptoms..
    C) ACUTE LUNG INJURY
    1) If fluorine or hydrogen fluoride is produced during thermal decomposition, anticipation of and treatment of pulmonary edema is the key objective.
    2) ONSET: Onset of acute lung injury after toxic exposure may be delayed up to 24 to 72 hours after exposure in some cases.
    3) NON-PHARMACOLOGIC TREATMENT: The treatment of acute lung injury is primarily supportive (Cataletto, 2012). Maintain adequate ventilation and oxygenation with frequent monitoring of arterial blood gases and/or pulse oximetry. If a high FIO2 is required to maintain adequate oxygenation, mechanical ventilation and positive-end-expiratory pressure (PEEP) may be required; ventilation with small tidal volumes (6 mL/kg) is preferred if ARDS develops (Haas, 2011; Stolbach & Hoffman, 2011).
    a) To minimize barotrauma and other complications, use the lowest amount of PEEP possible while maintaining adequate oxygenation. Use of smaller tidal volumes (6 mL/kg) and lower plateau pressures (30 cm water or less) has been associated with decreased mortality and more rapid weaning from mechanical ventilation in patients with ARDS (Brower et al, 2000). More treatment information may be obtained from ARDS Clinical Network website, NIH NHLBI ARDS Clinical Network Mechanical Ventilation Protocol Summary, http://www.ardsnet.org/node/77791 (NHLBI ARDS Network, 2008)
    4) FLUIDS: Crystalloid solutions must be administered judiciously. Pulmonary artery monitoring may help. In general the pulmonary artery wedge pressure should be kept relatively low while still maintaining adequate cardiac output, blood pressure and urine output (Stolbach & Hoffman, 2011).
    5) ANTIBIOTICS: Indicated only when there is evidence of infection (Artigas et al, 1998).
    6) EXPERIMENTAL THERAPY: Partial liquid ventilation has shown promise in preliminary studies (Kollef & Schuster, 1995).
    7) CALFACTANT: In a multicenter, randomized, blinded trial, endotracheal instillation of 2 doses of 80 mL/m(2) calfactant (35 mg/mL of phospholipid suspension in saline) in infants, children, and adolescents with acute lung injury resulted in acute improvement in oxygenation and lower mortality; however, no significant decrease in the course of respiratory failure measured by duration of ventilator therapy, intensive care unit, or hospital stay was noted. Adverse effects (transient hypoxia and hypotension) were more frequent in calfactant patients, but these effects were mild and did not require withdrawal from the study (Wilson et al, 2005).
    8) However, in a multicenter, randomized, controlled, and masked trial, endotracheal instillation of up to 3 doses of calfactant (30 mg) in adults only with acute lung injury/ARDS due to direct lung injury was not associated with improved oxygenation and longer term benefits compared to the placebo group. It was also associated with significant increases in hypoxia and hypotension (Willson et al, 2015).
    D) Treatment should include recommendations listed in the ORAL EXPOSURE section when appropriate.

Eye Exposure

    6.8.1) DECONTAMINATION
    A) EYE IRRIGATION, ROUTINE: Remove contact lenses and irrigate exposed eyes with copious amounts of room temperature 0.9% saline or water for at least 15 minutes. If irritation, pain, swelling, lacrimation, or photophobia persist after 15 minutes of irrigation, an ophthalmologic examination should be performed (Peate, 2007; Naradzay & Barish, 2006).

Dermal Exposure

    6.9.1) DECONTAMINATION
    A) DERMAL DECONTAMINATION
    1) DECONTAMINATION: Remove contaminated clothing and wash exposed area thoroughly with soap and water for 10 to 15 minutes. A physician may need to examine the area if irritation or pain persists (Burgess et al, 1999).
    6.9.2) TREATMENT
    A) FROSTBITE
    1) PREHOSPITAL
    a) Rewarming of a localized area should only be considered if the risk of refreezing is unlikely. Avoid rubbing the frozen area which may cause further damage to the area (Grieve et al, 2011; Hallam et al, 2010).
    2) REWARMING
    a) Do not institute rewarming unless complete rewarming can be assured; refreezing thawed tissue increases tissue damage. Place affected area in a water bath with a temperature of 40 to 42 degrees Celsius for 15 to 30 minutes until thawing is complete. The bath should be large enough to permit complete immersion of the injured part, avoiding contact with the sides of the bath. A whirlpool bath would be ideal. Some authors suggest a mild antibacterial (ie, chlorhexidine, hexachlorophene or povidone-iodine) be added to the bath water. Tissues should be thoroughly rewarmed and pliable; the skin will appear a red-purple color (Grieve et al, 2011; Hallam et al, 2010; Murphy et al, 2000).
    b) Correct systemic hypothermia which can cause cold diuresis due to suppression of antidiuretic hormone; consider IV fluids (Grieve et al, 2011).
    c) Rewarming may be associated with increasing acute pain, requiring narcotic analgesics.
    d) For severe frostbite, clinical trials have shown that pentoxifylline, a phosphodiesterase inhibitor, can enhance tissue viability by increasing blood flow and reducing platelet activity (Hallam et al, 2010).
    3) WOUND CARE
    a) Digits should be separated by sterile absorbent cotton; no constrictive dressings should be used. Protective dressings should be changed twice per day.
    b) Perform twice daily hydrotherapy for 30 to 45 minutes in warm water at 40 degrees Celsius. This helps debride devitalized tissue and maintain range of motion. Keep the area warm and dry between treatments (Hallam et al, 2010; Murphy et al, 2000).
    c) The injured extremities should be elevated and should not be allowed to bear weight.
    d) In patients at risk for infection of necrotic tissue, prophylactic antibiotics and tetanus toxoid have been recommended by some authors (Hallam et al, 2010; Murphy et al, 2000).
    e) Non-tense clear blisters should be left intact due to the risk of infection; tense or hemorrhagic blisters may be carefully aspirated in a setting where aseptic technique is provided (Hallam et al, 2010).
    f) Further surgical debridement should be delayed until mummification demarcation has occurred (60 to 90 days). Spontaneous amputation may occur.
    g) Analgesics may be required during the rewarming phase; however, patients with severe pain should be evaluated for vasospasm.
    h) IMAGING: Arteriography and noninvasive vascular techniques (e.g., plain radiography, laser Doppler studies, digital plethysmography, infrared thermography, isotope scanning), have been useful in evaluating the extent of vasospasm after thawing and assessing whether debridement is needed (Hallam et al, 2010). In cases of severe frostbite, Technetium 99 (triple phase scanning) and MRI angiography have been shown to be the most useful to assess injury and determine the extent or need for surgical debridement (Hallam et al, 2010).
    i) TOPICAL THERAPY: Topical aloe vera may decrease tissue destruction and should be applied every 6 hours (Murphy et al, 2000).
    j) IBUPROFEN THERAPY: Ibuprofen, a thromboxane inhibitor, may help limit inflammatory damage and reduce tissue loss (Grieve et al, 2011; Murphy et al, 2000). DOSE: 400 mg orally every 12 hours is recommended (Hallam et al, 2010).
    k) THROMBOLYTIC THERAPY: Thrombolysis (intra-arterial or intravenous thrombolytic agents) may be beneficial in those patients at risk to lose a digit or a limb, if done within the first 24 hours of exposure. The use of tissue plasminogen activator (t-PA) to clear microvascular thromboses can restore arterial blood flow, but should be accompanied by close monitoring including angiography or technetium scanning to evaluate the injury and to evaluate the effects of t-PA administration. Potential risk of the procedure includes significant tissue edema that can lead to a rise in interstitial pressures resulting in compartment syndrome (Grieve et al, 2011).
    l) CONTROVERSIAL: Adjunct pharmacological agents (ie, heparin, vasodilators, prostacyclins, prostaglandin synthetase inhibitors, dextran) are controversial and not routinely recommended. The role of hyperbaric oxygen therapy, sympathectomy remains unclear (Grieve et al, 2011).
    m) CHRONIC PAIN: Vasomotor dysfunction can produce chronic pain. Amitriptyline has been used in some patients; some patients may need a referral for pain management. Inability to tolerate the cold (in the affected area) has been observed following a single episode of frostbite (Hallam et al, 2010).
    n) MORBIDITIES: Frostbite can produce localized osteoporosis and possible bone loss following a severe case. These events may take a year or more to develop. Children may be at greater risk to develop more severe events (ie, early arthritis) (Hallam et al, 2010).
    B) Treatment should include recommendations listed in the ORAL EXPOSURE section when appropriate.

Summary

    A) Fluorinated hydrocarbons are very toxic when inhaled in high concentrations and/or for extended periods. At lower concentrations or brief exposure, they may cause transient eye, nose, and throat irritation. There is significant interindividual variation and it is difficult to predict which patient will exhibit symptoms following exposure.
    B) 1,1,1,2,3,3,3-Heptafluoropropane can displace sufficient oxygen from the air to act as a simple asphyxiant at concentrations greater than approximately 100,000 ppm. The effective fire extinguishing concentration is 7% (70,000 ppm).
    1) Signs of asphyxia will be noted when atmospheric oxygen is displaced to less than 15% to 16%, and unconsciousness leading to death will occur when it is less than 6% to 8%.

Minimum Lethal Exposure

    A) GENERAL/SUMMARY
    1) The minimum lethal human dose to this agent has not been delineated.
    2) Unconsciousness leading to death will occur when the atmospheric oxygen concentration is reduced to 6% to 8% or less (Kizer, 1984).

Maximum Tolerated Exposure

    A) GENERAL/SUMMARY
    1) The maximum tolerated human exposure to this agent has not been delineated.
    2) Fluorocarbons can be very toxic when sniffed in high concentrations and/or for extended periods. There can be significant variation in tolerance between individuals.
    B) ANIMAL DATA
    1) In rats, inhalation exposure to 1,1,2,3,3,3-heptafluoropropane at airborne concentrations of 1, 2, 5, and 10% (10,000, 20,000, 50,000, and 100,000 ppm) caused no toxicity in a 14-day repeated exposure study (Naas et al, 1995).
    2) Rats exposed to 2, 5, and 10.5% (20,000, 50,000, and 105,000 ppm) 6 hours daily, 5 days per week for 90 days developed no toxicity (Naas et al, 1995). Oxygen supplementation was given to the high dose group.
    a) The NOEL was 10.5% (105,000 ppm) in the above study (Naas et al, 1995).
    C) CASE REPORTS
    1) OCCUPATIONAL
    a) ARRHYTHMIAS - No clear connection between exposure and cardiac arrhythmias could be found in 6 refrigerator repairmen wearing ambulatory electrocardiographic monitors for 24 hours on the day of exposure and on a control day. Peak concentration and average level of exposure in the breathing zone were 3200 cm(3)/m(3) and 170 cm(3)/m(3), respectively (Antti-Poika et al, 1990).
    b) In animal experiments, much higher concentrations (100,000 to 200,000 cm(3)/m(3)) of fluorinated hydrocarbons were required for production of arrhythmias (Aviado & Micozzi, 1981).
    D) CONCENTRATION LEVEL
    1) ASPHYXIA - Signs of asphyxia will be noted when atmospheric oxygen is displaced such that the oxygen concentration is 15% to 16% or less (Kizer, 1984).

Serum Plasma Blood Concentrations

    7.5.2) TOXIC CONCENTRATIONS
    A) TOXIC CONCENTRATION LEVELS
    1) GENERAL
    a) The peak blood level occurs immediately after inhalation of many fluorocarbons. Within 15 minutes, the blood fluorocarbon is almost completely gone. The significance of blood levels in relationship to catecholamine-induced arrhythmias is unknown.

Workplace Standards

    A) ACGIH TLV Values for CAS431-89-0 (American Conference of Governmental Industrial Hygienists, 2010):
    1) Not Listed

    B) NIOSH REL and IDLH Values for CAS431-89-0 (National Institute for Occupational Safety and Health, 2007):
    1) Not Listed

    C) Carcinogenicity Ratings for CAS431-89-0 :
    1) ACGIH (American Conference of Governmental Industrial Hygienists, 2010): Not Listed
    2) EPA (U.S. Environmental Protection Agency, 2011): Not Listed
    3) IARC (International Agency for Research on Cancer (IARC), 2016; International Agency for Research on Cancer, 2015; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010a; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2008; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2007; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2006; IARC, 2004): Not Listed
    4) NIOSH (National Institute for Occupational Safety and Health, 2007): Not Listed
    5) MAK (DFG, 2002): Not Listed
    6) NTP (U.S. Department of Health and Human Services, Public Health Service, National Toxicology Project ): Not Listed

    D) OSHA PEL Values for CAS431-89-0 (U.S. Occupational Safety, and Health Administration (OSHA), 2010):
    1) Not Listed

Toxicologic Mechanism

    A) DERMAL EFFECTS - Fluorinated hydrocarbons have very low boiling points and may cause frostbite or freezing if in contact with skin for more than 3 to 5 seconds (ie, if sprayed directly from the aerosol at close range).
    B) DYSRHYTHMIAS - Autopsy findings in victims of sudden death associated with fluorinated hydrocarbon sniffing have been nonspecific (pulmonary edema, visceral congestion) suggesting dysrhythmia as the cause of death (Garriott & Petty, 1980; Smeeton, 1985).
    1) SUDDEN DEATH is often preceded by sudden exertion. It is postulated that fluorinated hydrocarbons cause sudden death by decreasing the myocardial threshold to the arrhythmogenic action of endogenous catecholamines (Smeeton, 1985).
    2) ANIMAL STUDIES - In dogs, inhalation of fluorinated hydrocarbon vapors causes bradycardia followed by junctional or ventricular escape rhythms, with deterioration to asystole or ventricular fibrillation in some animals (Flowers & Horan, 1972a; Flowers & Horan 1972b). This occurs despite maintenance of normal oxygen and carbon dioxide tensions, pH, base excess, and serum carbon dioxide.
    a) Epinephrine doses that produced minimal ECG alterations when administered alone, produced ventricular tachycardia and fibrillation when administered to dogs pretreated with the fluorocarbon, bromochlorodifluoromethane (Beck et al, 1973).
    3) IN VITRO - In isolated rat and human papillary muscles, dichlorodifluoromethane depresses contractility (Harris, 1973).
    C) THERMAL DECOMPOSITION - If fluorinated hydrocarbon vapors are thermally decomposed in open flames or arcs associated with furnaces, boilers, or welding operations, toxic gases such as fluorine and hydrogen fluoride are produced (Finkel, 1983).

Molecular Weight

    A) 170

General Bibliography

    1) 40 CFR 372.28: Environmental Protection Agency - Toxic Chemical Release Reporting, Community Right-To-Know, Lower thresholds for chemicals of special concern. National Archives and Records Administration (NARA) and the Government Printing Office (GPO). Washington, DC. Final rules current as of Apr 3, 2006.
    2) 40 CFR 372.65: Environmental Protection Agency - Toxic Chemical Release Reporting, Community Right-To-Know, Chemicals and Chemical Categories to which this part applies. National Archives and Records Association (NARA) and the Government Printing Office (GPO), Washington, DC. Final rules current as of Apr 3, 2006.
    3) 49 CFR 172.101 - App. B: Department of Transportation - Table of Hazardous Materials, Appendix B: List of Marine Pollutants. National Archives and Records Administration (NARA) and the Government Printing Office (GPO), Washington, DC. Final rules current as of Aug 29, 2005.
    4) 62 FR 58840: Notice of the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances - Proposed AEGL Values, Environmental Protection Agency, NAC/AEGL Committee. National Archives and Records Administration (NARA) and the Government Publishing Office (GPO), Washington, DC, 1997.
    5) 65 FR 14186: Notice of the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances - Proposed AEGL Values, Environmental Protection Agency, NAC/AEGL Committee. National Archives and Records Administration (NARA) and the Government Publishing Office (GPO), Washington, DC, 2000.
    6) 65 FR 39264: Notice of the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances - Proposed AEGL Values, Environmental Protection Agency, NAC/AEGL Committee. National Archives and Records Administration (NARA) and the Government Publishing Office (GPO), Washington, DC, 2000.
    7) 65 FR 77866: Notice of the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances - Proposed AEGL Values, Environmental Protection Agency, NAC/AEGL Committee. National Archives and Records Administration (NARA) and the Government Publishing Office (GPO), Washington, DC, 2000.
    8) 66 FR 21940: Notice of the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances - Proposed AEGL Values, Environmental Protection Agency, NAC/AEGL Committee. National Archives and Records Administration (NARA) and the Government Publishing Office (GPO), Washington, DC, 2001.
    9) 67 FR 7164: Notice of the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances - Proposed AEGL Values, Environmental Protection Agency, NAC/AEGL Committee. National Archives and Records Administration (NARA) and the Government Publishing Office (GPO), Washington, DC, 2002.
    10) 68 FR 42710: Notice of the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances - Proposed AEGL Values, Environmental Protection Agency, NAC/AEGL Committee. National Archives and Records Administration (NARA) and the Government Publishing Office (GPO), Washington, DC, 2003.
    11) 69 FR 54144: Notice of the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances - Proposed AEGL Values, Environmental Protection Agency, NAC/AEGL Committee. National Archives and Records Administration (NARA) and the Government Publishing Office (GPO), Washington, DC, 2004.
    12) AIHA: 2006 Emergency Response Planning Guidelines and Workplace Environmental Exposure Level Guides Handbook, American Industrial Hygiene Association, Fairfax, VA, 2006.
    13) American Conference of Governmental Industrial Hygienists : ACGIH 2010 Threshold Limit Values (TLVs(R)) for Chemical Substances and Physical Agents and Biological Exposure Indices (BEIs(R)), American Conference of Governmental Industrial Hygienists, Cincinnati, OH, 2010.
    14) Antti-Poika M, Heikkila J, & Sarrinen L: Cardiac arrhythmias during occupational exposure to fluorinated hydrocarbons. Br J Ind Med 1990; 47:138-140.
    15) Artigas A, Bernard GR, Carlet J, et al: The American-European consensus conference on ARDS, part 2: ventilatory, pharmacologic, supportive therapy, study design strategies, and issues related to recovery and remodeling.. Am J Respir Crit Care Med 1998; 157:1332-1347.
    16) Aviado DM & Micozzi MS: Fluorine-containing organic compounds, in Clayton GD & Clayton FE (eds): Patty's Industrial Hygiene and Toxicology, 3rd ed, John Wiley, New York, NY, 1981, pp 3071-3115.
    17) Beck PS, Clark DG, & Tinston DJ: The pharmacologic actions of bromochlorodifluoromethane (BCF). Toxicol Appl Pharmacol 1973; 24:20-29.
    18) Bowes WA III, Corke BC, & Hulka J: Pulse oximetry: a review of the theory, accuracy, and clinical applications. Obstet Gynecol 1989; 74:541-546.
    19) Brady WJ, Stremski E, & Eljaiek L: Freon inhalational abuse presenting with ventricular fibrillation. Am J Emerg Med 1994; 12:533-536.
    20) Brower RG, Matthay AM, & Morris A: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Eng J Med 2000; 342:1301-1308.
    21) Burgess JL, Kirk M, Borron SW, et al: Emergency department hazardous materials protocol for contaminated patients. Ann Emerg Med 1999; 34(2):205-212.
    22) Cataletto M: Respiratory Distress Syndrome, Acute(ARDS). In: Domino FJ, ed. The 5-Minute Clinical Consult 2012, 20th ed. Lippincott Williams & Wilkins, Philadelphia, PA, 2012.
    23) Chyka PA, Seger D, Krenzelok EP, et al: Position paper: Single-dose activated charcoal. Clin Toxicol (Phila) 2005; 43(2):61-87.
    24) Clark MA, Jones JW, & Robinson JJ: Multiple deaths resulting from shipboard exposure to trichlorotrifluoroethane. J Forensic Sci 1985; 30:1256-1259.
    25) Clayton GD & Clayton FE: Patty's Industrial Hygiene and Toxicology, Vol 2B. Toxicology, 4th ed, John Wiley & Sons, New York, NY, 1994, pp 1187-1189.
    26) Craig EV: A new high-pressure injection injury of the hand. J Hand Surg 1984; 9A:240-242.
    27) DFG: List of MAK and BAT Values 2002, Report No. 38, Deutsche Forschungsgemeinschaft, Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area, Wiley-VCH, Weinheim, Federal Republic of Germany, 2002.
    28) Denborough MA & Hopkkinson KC: Firefighting and malignant hyperthermia. Br Med J 1988; 296:1442-1443.
    29) EPA: Search results for Toxic Substances Control Act (TSCA) Inventory Chemicals. US Environmental Protection Agency, Substance Registry System, U.S. EPA's Office of Pollution Prevention and Toxics. Washington, DC. 2005. Available from URL: http://www.epa.gov/srs/.
    30) Elliot CG, Colby TV, & Kelly TM: Charcoal lung. Bronchiolitis obliterans after aspiration of activated charcoal. Chest 1989; 96:672-674.
    31) FDA: Poison treatment drug product for over-the-counter human use; tentative final monograph. FDA: Fed Register 1985; 50:2244-2262.
    32) Field GB: Occupational asthma due to heated freon (letter). Thorax 1985; 40:320.
    33) Finkel AJ: Hamilton and Hardy's Industrial Toxicology, 4th ed, John Wright, PSG Inc, Boston, MA, 1983, pp 241.
    34) Galdun JP, Paris PM, & Stewart RD: Pulse oximetry in the emergency department. Am J Emerg Med 1989; 7:422-425.
    35) Garriott J & Petty CS: Death from inhalant abuse: toxicologic and pathologic evaluation of 34 cases. Clin Toxicol 1980; 16:305-315.
    36) Goetting AT, Carson J, & Burton BT: Freon injection injury to the hand.. JOM 1992; 34:775-778.
    37) Golej J, Boigner H, Burda G, et al: Severe respiratory failure following charcoal application in a toddler. Resuscitation 2001; 49:315-318.
    38) Graff GR, Stark J, & Berkenbosch JW: Chronic lung disease after activated charcoal aspiration. Pediatrics 2002; 109:959-961.
    39) Grant M: Toxicology of the Eye, 3rd ed, CC Thomas Co, Springfield, IL, 1986.
    40) Grieve AW, Davis P, Dhillon S, et al: A clinical review of the management of frostbite. J R Army Med Corps 2011; 157(1):73-78.
    41) Haas CF: Mechanical ventilation with lung protective strategies: what works?. Crit Care Clin 2011; 27(3):469-486.
    42) Haj M, Burstein Z, & Horn E: Perforation of the stomach due to trichlorofluoromethane (Freon 11) ingestion. Isr J Med Sci 1980; 16:392-394.
    43) Hallam MJ, Cubison T, Dheansa B, et al: Managing frostbite. BMJ 2010; 341:c5864-.
    44) Harris CR & Filandrinos D: Accidental administration of activated charcoal into the lung: aspiration by proxy. Ann Emerg Med 1993; 22:1470-1473.
    45) Harris W: Toxic effects of aerosol propellants on the heart. Arch Intern Med 1973; 131:162-166.
    46) Holness DL & House RA: Health effects of Halon 1301 exposure. J Occup Med 1992; 34:722-725.
    47) IARC Working Group on the Evaluation of Carcinogenic Risks to Humans : IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: 1,3-Butadiene, Ethylene Oxide and Vinyl Halides (Vinyl Fluoride, Vinyl Chloride and Vinyl Bromide), 97, International Agency for Research on Cancer, Lyon, France, 2008.
    48) IARC Working Group on the Evaluation of Carcinogenic Risks to Humans : IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Formaldehyde, 2-Butoxyethanol and 1-tert-Butoxypropan-2-ol, 88, International Agency for Research on Cancer, Lyon, France, 2006.
    49) IARC Working Group on the Evaluation of Carcinogenic Risks to Humans : IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Household Use of Solid Fuels and High-temperature Frying, 95, International Agency for Research on Cancer, Lyon, France, 2010a.
    50) IARC Working Group on the Evaluation of Carcinogenic Risks to Humans : IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Smokeless Tobacco and Some Tobacco-specific N-Nitrosamines, 89, International Agency for Research on Cancer, Lyon, France, 2007.
    51) IARC Working Group on the Evaluation of Carcinogenic Risks to Humans : IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Some Non-heterocyclic Polycyclic Aromatic Hydrocarbons and Some Related Exposures, 92, International Agency for Research on Cancer, Lyon, France, 2010.
    52) IARC: List of all agents, mixtures and exposures evaluated to date - IARC Monographs: Overall Evaluations of Carcinogenicity to Humans, Volumes 1-88, 1972-PRESENT. World Health Organization, International Agency for Research on Cancer. Lyon, FranceAvailable from URL: http://monographs.iarc.fr/monoeval/crthall.html. As accessed Oct 07, 2004.
    53) International Agency for Research on Cancer (IARC): IARC monographs on the evaluation of carcinogenic risks to humans: list of classifications, volumes 1-116. International Agency for Research on Cancer (IARC). Lyon, France. 2016. Available from URL: http://monographs.iarc.fr/ENG/Classification/latest_classif.php. As accessed 2016-08-24.
    54) International Agency for Research on Cancer: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. World Health Organization. Geneva, Switzerland. 2015. Available from URL: http://monographs.iarc.fr/ENG/Classification/. As accessed 2015-08-06.
    55) Jones J, Heiselman D, & Cannon L: Continuous emergency department monitoring of arterial saturation in adult patients with respiratory distress. Ann Emerg Med 1988; 17:463-468.
    56) Kamm RC: Fatal arrhythmia following deodorant inhalation. Forens Sci 1975; 5:91-93.
    57) Kizer KW: Toxic inhalations. Emerg Med Clin North Am 1984; 2:649-666.
    58) Kollef MH & Schuster DP: The acute respiratory distress syndrome. N Engl J Med 1995; 332:27-37.
    59) Lerman Y, Winkler E, & Tirosh MS: Fatal accidental inhalation of bromochlorodifluoromethane (Halon 1211). Hum Exp Toxicol 1991; 10:125-128.
    60) Lown B: Electrical reversion of cardiac arrhythmias: in, Thorn et al (Eds): Harrison's Principal of Internal Medicine, 8th ed, McGraw-Hill, New York, NY, 1977, pp 1216-1219.
    61) Malo JL, Gagnon G, & Cartier A: Occupational asthma due to heated freon. Thorax 1984; 39:628-629.
    62) May DC & Blotzer MJ: A report of occupational deaths attributed to fluorocarbon-113. Arch Environ Health 1984; 39:352-354.
    63) McGee MB, Meyer RF, & Jejurikar SG: A death resulting from trichlorotrifluoroethane poisoning. J Forensic Sci 1990; 35:1453-1460.
    64) Morita M, Miki A, & Kazama H: Case report of deaths caused by freon gas. Forens Sci 1977; 10:253-260.
    65) Murphy JV, Banwell PE, & Roberts AHN: Frostbite: pathogenesis and treatment. J Trauma 2000; 48:171-178.
    66) NFPA: Fire Protection Guide to Hazardous Materials, 13th ed., National Fire Protection Association, Quincy, MA, 2002.
    67) NHLBI ARDS Network: Mechanical ventilation protocol summary. Massachusetts General Hospital. Boston, MA. 2008. Available from URL: http://www.ardsnet.org/system/files/6mlcardsmall_2008update_final_JULY2008.pdf. As accessed 2013-08-07.
    68) NRC: Acute Exposure Guideline Levels for Selected Airborne Chemicals - Volume 1, Subcommittee on Acute Exposure Guideline Levels, Committee on Toxicology, Board on Environmental Studies and Toxicology, Commission of Life Sciences, National Research Council. National Academy Press, Washington, DC, 2001.
    69) NRC: Acute Exposure Guideline Levels for Selected Airborne Chemicals - Volume 2, Subcommittee on Acute Exposure Guideline Levels, Committee on Toxicology, Board on Environmental Studies and Toxicology, Commission of Life Sciences, National Research Council. National Academy Press, Washington, DC, 2002.
    70) NRC: Acute Exposure Guideline Levels for Selected Airborne Chemicals - Volume 3, Subcommittee on Acute Exposure Guideline Levels, Committee on Toxicology, Board on Environmental Studies and Toxicology, Commission of Life Sciences, National Research Council. National Academy Press, Washington, DC, 2003.
    71) NRC: Acute Exposure Guideline Levels for Selected Airborne Chemicals - Volume 4, Subcommittee on Acute Exposure Guideline Levels, Committee on Toxicology, Board on Environmental Studies and Toxicology, Commission of Life Sciences, National Research Council. National Academy Press, Washington, DC, 2004.
    72) Naas DJ, Tompkins EC, & Varsho BJ: A 90-day subchronic toxicity study of 1,1,1,2,3,3,3-Heptafluoropropane (FM-200(TM)) in rats (Abstract # 973). Toxicologist 1995; 15:182.
    73) Naradzay J & Barish RA: Approach to ophthalmologic emergencies. Med Clin North Am 2006; 90(2):305-328.
    74) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for 1,2,3-Trimethylbenzene (Proposed). United States Environmental Protection Agency. Washington, DC. 2006k. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020d68a&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    75) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for 1,2,4-Trimethylbenzene (Proposed). United States Environmental Protection Agency. Washington, DC. 2006m. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020d68a&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    76) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for 1,2-Butylene Oxide (Proposed). United States Environmental Protection Agency. Washington, DC. 2008d. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648083cdbb&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    77) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for 1,2-Dibromoethane (Proposed). United States Environmental Protection Agency. Washington, DC. 2007g. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064802796db&disposition=attachment&contentType=pdf. As accessed 2010-08-18.
    78) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for 1,3,5-Trimethylbenzene (Proposed). United States Environmental Protection Agency. Washington, DC. 2006l. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020d68a&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    79) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for 2-Ethylhexyl Chloroformate (Proposed). United States Environmental Protection Agency. Washington, DC. 2007b. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648037904e&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    80) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Acrylonitrile (Proposed). United States Environmental Protection Agency. Washington, DC. 2007c. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648028e6a3&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    81) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Adamsite (Proposed). United States Environmental Protection Agency. Washington, DC. 2007h. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020fd29&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    82) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Agent BZ (3-quinuclidinyl benzilate) (Proposed). United States Environmental Protection Agency. Washington, DC. 2007f. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064803ad507&disposition=attachment&contentType=pdf. As accessed 2010-08-18.
    83) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Allyl Chloride (Proposed). United States Environmental Protection Agency. Washington, DC. 2008. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648039d9ee&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    84) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Aluminum Phosphide (Proposed). United States Environmental Protection Agency. Washington, DC. 2005b. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020c5ed&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    85) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Arsenic Trioxide (Proposed). United States Environmental Protection Agency. Washington, DC. 2007m. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480220305&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    86) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Automotive Gasoline Unleaded (Proposed). United States Environmental Protection Agency. Washington, DC. 2009a. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a7cc17&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    87) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Biphenyl (Proposed). United States Environmental Protection Agency. Washington, DC. 2005j. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064801ea1b7&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    88) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Bis-Chloromethyl Ether (BCME) (Proposed). United States Environmental Protection Agency. Washington, DC. 2006n. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648022db11&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    89) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Boron Tribromide (Proposed). United States Environmental Protection Agency. Washington, DC. 2008a. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064803ae1d3&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    90) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Bromine Chloride (Proposed). United States Environmental Protection Agency. Washington, DC. 2007d. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648039732a&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    91) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Bromoacetone (Proposed). United States Environmental Protection Agency. Washington, DC. 2008e. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064809187bf&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    92) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Calcium Phosphide (Proposed). United States Environmental Protection Agency. Washington, DC. 2005d. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020c5ed&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    93) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Carbonyl Fluoride (Proposed). United States Environmental Protection Agency. Washington, DC. 2008b. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064803ae328&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    94) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Carbonyl Sulfide (Proposed). United States Environmental Protection Agency. Washington, DC. 2007e. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648037ff26&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    95) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Chlorobenzene (Proposed). United States Environmental Protection Agency. Washington, DC. 2008c. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064803a52bb&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    96) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Cyanogen (Proposed). United States Environmental Protection Agency. Washington, DC. 2008f. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064809187fe&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    97) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Dimethyl Phosphite (Proposed). United States Environmental Protection Agency. Washington, DC. 2009. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a7cbf3&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    98) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Diphenylchloroarsine (Proposed). United States Environmental Protection Agency. Washington, DC. 2007l. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020fd29&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    99) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Ethyl Isocyanate (Proposed). United States Environmental Protection Agency. Washington, DC. 2008h. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648091884e&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    100) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Ethyl Phosphorodichloridate (Proposed). United States Environmental Protection Agency. Washington, DC. 2008i. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480920347&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    101) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Ethylbenzene (Proposed). United States Environmental Protection Agency. Washington, DC. 2008g. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064809203e7&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    102) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Ethyldichloroarsine (Proposed). United States Environmental Protection Agency. Washington, DC. 2007j. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020fd29&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    103) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Germane (Proposed). United States Environmental Protection Agency. Washington, DC. 2008j. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480963906&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    104) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Hexafluoropropylene (Proposed). United States Environmental Protection Agency. Washington, DC. 2006. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064801ea1f5&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    105) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Ketene (Proposed). United States Environmental Protection Agency. Washington, DC. 2007. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020ee7c&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    106) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Magnesium Aluminum Phosphide (Proposed). United States Environmental Protection Agency. Washington, DC. 2005h. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020c5ed&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    107) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Magnesium Phosphide (Proposed). United States Environmental Protection Agency. Washington, DC. 2005g. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020c5ed&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    108) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Malathion (Proposed). United States Environmental Protection Agency. Washington, DC. 2009k. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064809639df&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    109) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Mercury Vapor (Proposed). United States Environmental Protection Agency. Washington, DC. 2009b. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a8a087&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    110) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Methyl Isothiocyanate (Proposed). United States Environmental Protection Agency. Washington, DC. 2008k. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480963a03&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    111) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Methyl Parathion (Proposed). United States Environmental Protection Agency. Washington, DC. 2008l. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480963a57&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    112) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Methyl tertiary-butyl ether (Proposed). United States Environmental Protection Agency. Washington, DC. 2007a. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064802a4985&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    113) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Methylchlorosilane (Proposed). United States Environmental Protection Agency. Washington, DC. 2005. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020c5f4&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    114) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Methyldichloroarsine (Proposed). United States Environmental Protection Agency. Washington, DC. 2007i. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020fd29&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    115) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Methyldichlorosilane (Proposed). United States Environmental Protection Agency. Washington, DC. 2005a. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020c646&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    116) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Nitrogen Mustard (HN1 CAS Reg. No. 538-07-8) (Proposed). United States Environmental Protection Agency. Washington, DC. 2006a. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020d6cb&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    117) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Nitrogen Mustard (HN2 CAS Reg. No. 51-75-2) (Proposed). United States Environmental Protection Agency. Washington, DC. 2006b. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020d6cb&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    118) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Nitrogen Mustard (HN3 CAS Reg. No. 555-77-1) (Proposed). United States Environmental Protection Agency. Washington, DC. 2006c. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020d6cb&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    119) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Nitrogen Tetroxide (Proposed). United States Environmental Protection Agency. Washington, DC. 2008n. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648091855b&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    120) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Nitrogen Trifluoride (Proposed). United States Environmental Protection Agency. Washington, DC. 2009l. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480963e0c&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    121) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Parathion (Proposed). United States Environmental Protection Agency. Washington, DC. 2008o. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480963e32&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    122) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Perchloryl Fluoride (Proposed). United States Environmental Protection Agency. Washington, DC. 2009c. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a7e268&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    123) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Perfluoroisobutylene (Proposed). United States Environmental Protection Agency. Washington, DC. 2009d. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a7e26a&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    124) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Phenyl Isocyanate (Proposed). United States Environmental Protection Agency. Washington, DC. 2008p. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648096dd58&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    125) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Phenyl Mercaptan (Proposed). United States Environmental Protection Agency. Washington, DC. 2006d. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020cc0c&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    126) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Phenyldichloroarsine (Proposed). United States Environmental Protection Agency. Washington, DC. 2007k. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020fd29&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    127) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Phorate (Proposed). United States Environmental Protection Agency. Washington, DC. 2008q. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648096dcc8&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    128) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Phosgene (Draft-Revised). United States Environmental Protection Agency. Washington, DC. 2009e. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a8a08a&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    129) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Phosgene Oxime (Proposed). United States Environmental Protection Agency. Washington, DC. 2009f. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a7e26d&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    130) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Potassium Cyanide (Proposed). United States Environmental Protection Agency. Washington, DC. 2009g. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a7cbb9&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    131) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Potassium Phosphide (Proposed). United States Environmental Protection Agency. Washington, DC. 2005c. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020c5ed&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    132) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Propargyl Alcohol (Proposed). United States Environmental Protection Agency. Washington, DC. 2006e. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020ec91&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    133) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Selenium Hexafluoride (Proposed). United States Environmental Protection Agency. Washington, DC. 2006f. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020ec55&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    134) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Silane (Proposed). United States Environmental Protection Agency. Washington, DC. 2006g. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020d523&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    135) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Sodium Cyanide (Proposed). United States Environmental Protection Agency. Washington, DC. 2009h. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a7cbb9&disposition=attachment&contentType=pdf. As accessed 2010-08-15.
    136) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Sodium Phosphide (Proposed). United States Environmental Protection Agency. Washington, DC. 2005i. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020c5ed&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    137) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Strontium Phosphide (Proposed). United States Environmental Protection Agency. Washington, DC. 2005f. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020c5ed&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    138) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Sulfuryl Chloride (Proposed). United States Environmental Protection Agency. Washington, DC. 2006h. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020ec7a&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    139) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Tear Gas (Proposed). United States Environmental Protection Agency. Washington, DC. 2008s. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648096e551&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    140) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Tellurium Hexafluoride (Proposed). United States Environmental Protection Agency. Washington, DC. 2009i. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a7e2a1&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    141) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Tert-Octyl Mercaptan (Proposed). United States Environmental Protection Agency. Washington, DC. 2008r. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648096e5c7&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    142) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Tetramethoxysilane (Proposed). United States Environmental Protection Agency. Washington, DC. 2006j. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020d632&disposition=attachment&contentType=pdf. As accessed 2010-08-17.
    143) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Trimethoxysilane (Proposed). United States Environmental Protection Agency. Washington, DC. 2006i. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020d632&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    144) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Trimethyl Phosphite (Proposed). United States Environmental Protection Agency. Washington, DC. 2009j. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=0900006480a7d608&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    145) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Trimethylacetyl Chloride (Proposed). United States Environmental Protection Agency. Washington, DC. 2008t. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648096e5cc&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    146) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for Zinc Phosphide (Proposed). United States Environmental Protection Agency. Washington, DC. 2005e. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020c5ed&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    147) National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances: Acute Exposure Guideline Levels (AEGLs) for n-Butyl Isocyanate (Proposed). United States Environmental Protection Agency. Washington, DC. 2008m. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=09000064808f9591&disposition=attachment&contentType=pdf. As accessed 2010-08-12.
    148) National Heart,Lung,and Blood Institute: Expert panel report 3: guidelines for the diagnosis and management of asthma. National Heart,Lung,and Blood Institute. Bethesda, MD. 2007. Available from URL: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf.
    149) National Institute for Occupational Safety and Health: NIOSH Pocket Guide to Chemical Hazards, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Cincinnati, OH, 2007.
    150) National Research Council : Acute exposure guideline levels for selected airborne chemicals, 5, National Academies Press, Washington, DC, 2007.
    151) National Research Council: Acute exposure guideline levels for selected airborne chemicals, 6, National Academies Press, Washington, DC, 2008.
    152) National Research Council: Acute exposure guideline levels for selected airborne chemicals, 7, National Academies Press, Washington, DC, 2009.
    153) National Research Council: Acute exposure guideline levels for selected airborne chemicals, 8, National Academies Press, Washington, DC, 2010.
    154) Nemec MJ, Holson J, & Naas D: An assessment of the potential developmental toxicity of heptafluoropropane (FM-200) by inhalation in the rat. Teratology 1994; 49:420.
    155) None Listed: Position paper: cathartics. J Toxicol Clin Toxicol 2004; 42(3):243-253.
    156) Peate WF: Work-related eye injuries and illnesses. Am Fam Physician 2007; 75(7):1017-1022.
    157) Personal Communication: Personal Communication: William L Sprout, MD. Dupont, Newark, DE, 1988.
    158) Phillips GD, Runciman WB, & Ilsley AH: Monitoring in emergency medicine. Resuscitation 1989; 18:S21-S35.
    159) Pollack MM, Dunbar BS, & Holbrook PR: Aspiration of activated charcoal and gastric contents. Ann Emerg Med 1981; 10:528-529.
    160) Proctor N & Hughes J: Chemical Hazards of the Workplace, Lippincott Co, Philadelphia, PA, 1978.
    161) Rasmussen K, Jeppesen HJ, & Arlien-Soborg P: Psychoorganic syndrome from exposure to Fluorocarbon 113 - an occupational disease?. Eur Neurol 1988; 28:205-207.
    162) Rau NR, Nagaraj MV, Prakash PS, et al: Fatal pulmonary aspiration of oral activated charcoal. Br Med J 1988; 297:918-919.
    163) Rose CC & Wolfson AB: Respiratory physiology. Emerg Med Clin North Am 1989; 7:187-204.
    164) Smeeton WMI: Sudden death resulting from inhalation of fire extinguishers containing brmochlorodifluoromethane. Med Sci Law 1985; 25:258-262.
    165) Steadman C, Dorrington LC, & Kay P: Abuse of a fire-extinguishing agent and sudden death in adolescents. Med J Aust 1984; 141:115-117.
    166) Stolbach A & Hoffman RS: Respiratory Principles. In: Nelson LS, Hoffman RS, Lewin NA, et al, eds. Goldfrank's Toxicologic Emergencies, 9th ed. McGraw Hill Medical, New York, NY, 2011.
    167) U.S. Department of Energy, Office of Emergency Management: Protective Action Criteria (PAC) with AEGLs, ERPGs, & TEELs: Rev. 26 for chemicals of concern. U.S. Department of Energy, Office of Emergency Management. Washington, DC. 2010. Available from URL: http://www.hss.doe.gov/HealthSafety/WSHP/Chem_Safety/teel.html. As accessed 2011-06-27.
    168) U.S. Department of Health and Human Services, Public Health Service, National Toxicology Project : 11th Report on Carcinogens. U.S. Department of Health and Human Services, Public Health Service, National Toxicology Program. Washington, DC. 2005. Available from URL: http://ntp.niehs.nih.gov/INDEXA5E1.HTM?objectid=32BA9724-F1F6-975E-7FCE50709CB4C932. As accessed 2011-06-27.
    169) U.S. Environmental Protection Agency: Discarded commercial chemical products, off-specification species, container residues, and spill residues thereof. Environmental Protection Agency's (EPA) Resource Conservation and Recovery Act (RCRA); List of hazardous substances and reportable quantities 2010b; 40CFR(261.33, e-f):77-.
    170) U.S. Environmental Protection Agency: Integrated Risk Information System (IRIS). U.S. Environmental Protection Agency. Washington, DC. 2011. Available from URL: http://cfpub.epa.gov/ncea/iris/index.cfm?fuseaction=iris.showSubstanceList&list_type=date. As accessed 2011-06-21.
    171) U.S. Environmental Protection Agency: List of Radionuclides. U.S. Environmental Protection Agency. Washington, DC. 2010a. Available from URL: http://www.gpo.gov/fdsys/pkg/CFR-2010-title40-vol27/pdf/CFR-2010-title40-vol27-sec302-4.pdf. As accessed 2011-06-17.
    172) U.S. Environmental Protection Agency: List of hazardous substances and reportable quantities. U.S. Environmental Protection Agency. Washington, DC. 2010. Available from URL: http://www.gpo.gov/fdsys/pkg/CFR-2010-title40-vol27/pdf/CFR-2010-title40-vol27-sec302-4.pdf. As accessed 2011-06-17.
    173) U.S. Environmental Protection Agency: The list of extremely hazardous substances and their threshold planning quantities (CAS Number Order). U.S. Environmental Protection Agency. Washington, DC. 2010c. Available from URL: http://www.gpo.gov/fdsys/pkg/CFR-2010-title40-vol27/pdf/CFR-2010-title40-vol27-part355.pdf. As accessed 2011-06-17.
    174) U.S. Occupational Safety and Health Administration: Part 1910 - Occupational safety and health standards (continued) Occupational Safety, and Health Administration's (OSHA) list of highly hazardous chemicals, toxics and reactives. Subpart Z - toxic and hazardous substances. CFR 2010 2010; Vol6(SEC1910):7-.
    175) U.S. Occupational Safety, and Health Administration (OSHA): Process safety management of highly hazardous chemicals. 29 CFR 2010 2010; 29(1910.119):348-.
    176) United States Environmental Protection Agency Office of Pollution Prevention and Toxics: Acute Exposure Guideline Levels (AEGLs) for Vinyl Acetate (Proposed). United States Environmental Protection Agency. Washington, DC. 2006. Available from URL: http://www.regulations.gov/search/Regs/contentStreamer?objectId=090000648020d6af&disposition=attachment&contentType=pdf. As accessed 2010-08-16.
    177) Valdivieso R, Pola J, & Zapata C: Contact allergic dermatitis caused by Freon 1 in deodorants. Contact Derm 1987; 17:243-245.
    178) Voge VM: Freon: an unsuspected problem. Aviat Space Environ Med 1989; 60(Suppl 10):B27-B28.
    179) Wegener EE, Barraza KR, & Das SK: Severe frostbite caused by freon gas. South Med J 1991; 84:1143-1146.
    180) Willson DF, Truwit JD, Conaway MR, et al: The adult calfactant in acute respiratory distress syndrome (CARDS) trial. Chest 2015; 148(2):356-364.
    181) Wilson DF, Thomas NJ, Markovitz BP, et al: Effect of exogenous surfactant (calfactant) in pediatric acute lung injury. A randomized controlled trial. JAMA 2005; 293:470-476.
    182) Winograd HL: Acute croup in an older child. An unusual toxic origin. Clin Pediatr 1977; 16:884-887.
    183) Yelderman M & New W Jr: Evaluation of pulse oximetry. Anesthesiology 1983; 59:349-352.